Training myeloid suppressive programs in cancer
Myeloid cells are the most abundant leukocyte population in solid tumors. In contrast to the
Menú
The Casanova Acebes Lab focuses on understanding how innate immune cells behave, respond, and shape adaptive immunity in the tumor microenvironment. We are interested in the molecular and functional plasticity of innate immune cells in solid tumors, mainly focusing our efforts on lung, ovarian, and breast cancer.
Myeloid cells are the most abundant leukocyte population in solid tumors. In contrast to the
Metastasis occurs when the most aggressive tumor cells disseminate and grow in other organs. The
Innate immune cells activity relies onthe tissue in which they reside. This is mainly driven by the unique signals they receive in every tissue and in tumors. To decode those signals, and investigate the messages that innate immune cells receive, our projects focus on aspects related to innate immune dynamics, ontogeny, metabolic properties, and plasticity in different tumor micro environments.
Metastasis occurs when the most aggressive tumor cells disseminate and grow in other organs. The immune system is our major defense against cancer, as it recognizes malignant cells being capable to eliminate them.
Immune checkpoint blockade (ICB) has revolutionized cancer care yet is ineffective in most patients. Predicting which patients will respond to ICB and how to enhance efficacy are major challenges. ICB efficacy is dependent on the presence of functional T cells in tumors, which are impacted by macrophages.
Myeloid cells are the most abundant leukocyte population in solid tumors. In contrast to the heterogeneity found in tumoral macrophages (tM𝜑s), the diversity of short-lived lineages such as neutrophils (Neu), monocytes (Mo) and their progenitors, is only starting to be appreciated. Interestingly, growing evidence suggests that epigenetic reprogramming of myeloid cells upon exogenous or endogenous insults leads to an altered response to subsequent triggers, which can favor disease progression.